Stargardt Disease Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Stargardt Disease remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 45 matched trial records and 26 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07594236 | Intervention not normalized | Phase 1; Recruiting | Sponsor not listed | United States | Incidence of Ocular and Systemic Adverse Events (3 months) | 2028-12-31 |
| NCT07502664 | Intervention not normalized | Not Applicable; Recruiting | Ray Therapeutics, Inc. | United States | Operational feasibility of testing moderate to profound vision impaired patients with various retinal dystrophies on a battery of visual assessments (3 months) | 2027-02-01 |
| NCT07439887 | RTX-021 | Phase 1/2; Recruiting | Ray Therapeutics, Inc. | United States | Incidence of Treatment-Emergent Adverse Events (6 Months) | 2030-12-01 |
| NCT07425574 | Intervention not normalized | Not Applicable; Recruiting | Astellas Pharma Global Development, Inc. | United States | Change from baseline in best corrected visual acuity (BCVA) at month 12 (Baseline and Month 12) | 2028-07-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease (Phase 2): the indexed record reports Mean Rate of Change in the Area of Ellipsoid Zone Defect From Baseline Through Month 18(Least Squares Mean) = 0.6383 mm^2/18 months (Standard Error, 0.1113); Mean Rate of Change in the Area of Ellipsoid Zone Defect From Baseline Through Month 18(Least Squares Mean): difference in LS mean = -0.0261(95% CI, -0.3334 to 0.2813), P-Value = 0.8669; Mean Rate of Change in the Area of Ellipsoid Zone Defect From Baseline Through Month 18(Least Squares Mean): difference in LS mean = -0.0261(95% CI, -0.3334 to 0.2813), P-Value = 0.8669.
- A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights (Phase 1): the indexed record reports TEAE = totalling 30 events (73% Grade 1, 27% Grade 2) Pts; TEAE = 8 Pts; TEAE = totalling 30 events (73% Grade 1, 27% Grade 2) Pts.
- New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease (Phase 3): the indexed record reports Growth rate of atrophic retinal lesions(DDAF, study eye): Difference (%) = -35.7, P-Value = 0.0033 Met; Growth rate of atrophic retinal lesions(DDAF, study eye): Difference (%) = -35.7, P-Value = 0.0033 Met.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including RTX-021 (Phase 1/2). Company & Deal Intelligence records identify sponsor context for Ray Therapeutics, Inc., Astellas Pharma Global Development, Inc.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Endpoints that capture daily function and treatment burden alongside biological change.
- Long-duration comparisons against current procedural or pharmacologic standards.
- Evidence across diverse ages, disease stages and reproductive contexts.
- Delivery approaches that improve persistence without sacrificing safety.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Stargardt Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
